Nasdaq · CIK 0000730272
RGEN REPLIGEN CORP
C
60 / 100
Material weaknesses
2
Restatements
0
Auditor changes
0
Late filings
0
Quarters with open weakness
1
Remediations
0
Deductions
40
Remediation credit
0
Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.
Disclosures, in the company's words
“Irrespective of the effects of the IT general controls deficiencies, management did not perform certain business process-level controls related to inventory valuation and the financial statement close process either in a timely manner or with an appropriate precision threshold.”
“Management did not maintain effective information technology ( IT ) general controls for information systems that are relevant to the preparation of our financial statements. Specifically, we did not maintain logical access controls and program change management controls to ensure that access to programs and data are appropriately restricted and program and data changes are identified, tested, authorized and implemented appropriately.”
“the principal executive officer and principal financial officer have concluded that, as of the end of such period, the Company s disclosure controls and procedures were not effective because of the previously reported material weaknesses in our internal control over financial reporting”
Filings read
- 10-Q · 2026-10-30read
- 10-Q · 2026-07-29queued
- 8-K · 2026-07-22queued
- 10-Q · 2026-05-06queued
- 10-K · 2026-02-26queued
- 10-Q · 2025-11-04queued
- 10-Q · 2025-08-07queued
- 10-Q · 2025-04-29queued
- 10-K · 2025-03-14queued
- 10-Q/A · 2024-11-18queued
- 10-Q/A · 2024-11-18queued
- 10-Q/A · 2024-11-18queued
- 10-Q/A · 2024-11-18queued
- 10-Q · 2024-11-18queued
- 10-Q/A · 2024-11-18queued
- 10-K/A · 2024-11-18queued
Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.